Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients

Carcinogenesis

Volumn 17, Issue 9, 1996, Pages 1923-1929

  Anwar, W A ^a   Abdel Rahman, S Z ^b   El Zein, R A ^b   Mostafa, H M ^c   Au, W W ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; EGYPT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK;

EID: 0029833473     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/17.9.1923     Document Type: Article

References (74)

1. Boring, C.C., Squires, T.S., Tong, T. and Montgomery, S. (1994) Cancer statistics 1994. CA Cancer J. Clin., 44, 7-17.
2. Ibrahim, S.A. (1986) Site distribution of cancer in Egypt. Twelve years experience. (1970-1981). In Kogali, M., Omar, Y.T., Gjorgov, A. and Ismail, A.S. (eds), Cancer Prevention in Developing Countries. Pergamon Press, Oxford, pp. 45-50.
3. Lucas, S.B. (1982) Bladder tumors in Malawi. Br. J. Urol., 54, 275-279.
4. WHO (1985) (World Health Organization) The Control of Schistosomiasis. Report of WHO expert committee. Technical Report Series No. 728. WHO, Geneva.
5. WHO (1986) (World Health Organization) The Epidemiological Association Between Schistosoma haematobium infection and Bladder Cancer. Technical Report Series No, 186 86. WHO Geneva.
6. Essa, M.M., Mangoud, A.M., Aly, M.A., El-Adl, M. and Morsy, T.A. (1990) Schistosomiasis associated bladder carcinoma expression of cytokeratin. J. Egypt. Soc. Parasitol., 20, 161-167.
7. McCully, R.M., Baron, C.N. and Cheever, A.W. (1976) Schistosomiasis (Bilharziasis). In Bindford, C.H. and Connor, D.H. (eds), Pathology of Tropical and Extraordinary Diseases. Armed Forces Institute of Pathology, Washington, DC, pp. 428-508.
8. UICC (1970) (Union International Contre le Cancer) Cancer Incidence in Five Continents. vol.2, Springer-Verlag, Berlin.
9. Hicks, R.M., James, C.L. and Webbe, G. (1980) Effect of Schistosoma haematobium and N-butyl-N-(4-hydroxybutyl) nitrosamine on the development of urothelial neoplasia in the baboon. Br. J. Cancer, 42, 730-755.
10. Hicks, R.M. (1982) Nitrosamines as possible etiological agents in bilharzial bladder cancer. In Magee, P.N. (ed.), Banbury Report No. 12: Nitrosamines and Human Cancer. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 455-471.
11. Gentille, J. (1985) Schistosome related cancers, a possible role for genotoxins. Environ. Mutagen., 775-785.
12. Tricker, A.R., Spielhader, B. and Preussman, R. (1989) Environmental exposure to preformed N-nitroso compounds and nitrosating agents in human cancer etiology. Pharmacogenetics, 2, 272-277.
13. Mostafa, M.H., Helmi, S., Badawi, A.F., Tricker, A.R., Spiegelhalder, B. and Preussmann, R. (1994) Nitrate, nitrite and volatile nitroso compounds in the urine of Schistosoma haematobium and Schistosoma mansoni infected patients. Carcinogenesis, 15, 619-625.
14. Wolf, C.R. (1986) Cytochrome P450s: a multigene family involved in carcinogen metabolism. Trends Genet., 2, 209-214.
15. Guengerich, F.P. (1990) Characterization of the roles of human cytochrome P450 enzymes in carcinogen metabolism. Asia Pacific J. Pharmacol., 5, 327-345.
16. Mannervik, B., Awasthi, Y.C., Board, P.G. et al. (1992). Nomenclature for human glutathione transferases. Biochem. J., 282, 305-306.
17. Idle, J. (1991) Is environmental carcinogenesis modulated by host polymorphism? Mutat. Res., 247, 259-266.
18. Nebert, D.W. (1991) Polymorphism of human CYP2D6 genes involved in drug metabolism: Possible relationship to individual cancer risk. Cancer Cell, 3, 93-96.
19. Harris, C.C. (1991) Chemical and physical carcinogens: Advances and perspectives for the 1990s. Cancer Res., 51 (Suppl.), 5023s-5044s.
20. Kaisary, A., Smith, P., Jaczq, C., McAllister, C.B., Wilkinson, G.R., Ray, W.A. and Branch, R.A. (1987) Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res., 47, 5488-5493.
21. Fleming, C.M., Kaisary, A., Wilkinson, G.R. and Branch, R.A. (1992) The ability to 4-hydroxylate debrisoquine is related Io recurrence of bladder cancer. Pharmacogenetics, 2, 128-134.
22. Persaad, R.A., Fleming, C.M., Wilkinson, G.R., Smith, P.J. and Branch, R.A. (1992) Bladder cancer recurrence and its association with cytochrome P450 2D6 activity. Prog. Clin. Biol. Res., 378, 19-27.
23. Romkes-Sparks, M., Nuskin, A., Chern, H., Persad, R., Fleming, C., Sibley, G.N.A., Smith, P., Wilkinson, G.R. and Branch, R.A. (1994). Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Carcinogenesis, 15, 1955-1961.
24. Guengerich, F.P., Kim, D.H. and Iwasaki, M. (1991) Role of human cytochrome P450 IIEI in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol., 4, 168-179.
25. Smith, T.J., Guo, Z., Gonzalez, F.J., Guengerich, F.P., Stoner, G.D. and Yang, C.S. (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes p-450 expressed in hepatoma cells. Cancer Res., 52, 1757-1563.
26. Camus, A.M., Geneste, O. Honkakoski, P., B'er'eziat, J.C., Wolf, C.R., Bartsch, H. and Lang, M.A. (1993) High variability of nitrosamine metabolism among individuals: role of cytochrome P450 A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol. Carcinogen., 7, 268-275.
27. Kazakoff, K., Iversen, P., Lawson, T., Baron, J., Guengerich, F.P. and Pour, P.M. (1994) Involvement of cytochrome P450 2E1-like isoform in the activation of N-nitrosobis (2-oxopropyl) amine in the rat nasal mucosa. Eur. J. Cancer Oral Oncol., 30B(3), 179-185.
28. Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, R. and Watanabe, M. (1991) Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J. Cancer Res., 82, 254-256.
29. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A. and Vainio, H. (1993) The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphism in a finnish study population. Carcinogenesis, 14, 85-88.
30. Kato, S., Shields, P.G., Caporaso, N.E., Hoover, R.N., Trump, B.F., Sugimura, H., Weston, A. and Harris, C.C. (1992) Cytochrome P450IIEI genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res., 52, 6712-6715.
31. Kato, S., Shields, P.G., Caporaso, N.E., Sugimura, H., Trivers, G.E., Tucker, M.A., Trump, B.F., Weston, A. and Harris, C.C. (1994) Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomarkers Prev., 3, 515-518.
32. Roots, L., Drakoulis, N. and Brokmoller, J. (1992) Polymorphic enzymes and cancer risk: concepts, methodology and data review. In Kalow, W. (ed.), Pharmacogenetics of Drug Metabolism. Pergamon Press, New York, pp. 815-841.
33. Awasthi, Y.C., Sharma, R. and Singhal, S.S. (1994) Human glutathione S-transferases. Int. J. Biochem., 26, 295-308.
34. Seidegard, J. and Pero, R.W. (1985) The hereditary transmission of high glutathione transferase activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum. Genet., 69, 66-68.
35. Mannervik, B., Alin, P., Guthenberg, C., Jensson, H., Tahir, M.K., Warholm, M. and Jornoval, H. (1985) Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc. Natl Acad. Sci. USA, 82, 7202-7206.
36. Seidegard, J. Vorachek, W.R., Pero, R.W. and Pearson, W.R. (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl Acad. Sci. USA, 85, 7293-7297.
37. Lin, H.J. Han, C.Y., Bernstein, D.A., Hsiao, W. and Lin, B.K. (1994) Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis, 1, 1077-1081.
38. Bell, D.A., Taylor, J.A., Paulson, D.F., Robertson, C.N., Mohler, J.L. and Lucier, G.W. (1993) Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl Cancer Inst., 85, 1159-1164.
39. Lafuente, A., Pujol, F., Carretero, P., Villa, J.P. and Guchi, A. (1993) Human glutathione S-transferase μ (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett., 68, 49-54.
40. Brokmoller, J., Kerb, R., Drakoulis, N., Staffeldt, B. and Roots, I. (1994) Glutathione S- transferase M1 and its variant A and B as host factors of bladder cancer susceptibility: A case control study. Cancer Res., 54, 4103-4111.
41. Board, P., Coggan, M., Johnston, P., Ross, V., Suzuki, T. and Webb, G. (1990) Genetic heterogeneity of the human glutathione transferases: a complex of gene families. Pharmacol. Ther., 48, 357-369.
42. Rannung, A., Alexandrie, A., Persson, I. and Ingelman-Sundberg, M. (1995) Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. JOEM, 37, 25-36.
43. 14C]acrylonitrile with DNA in gastric tissue of rat. J. Biochem. Toxicol., 9, 191-198.
44. Sambrook, J., Fritsch, E.F and Maniatis, T. (1989) Molecular Cloning. A Laboratory Manual. 2nd edn, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 9-19.
45. Hayashi, S., Watanabe, J. and Kawajiri, K. (1991) Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIEI gene. Biochemistry, 110, 559-565.
46. Cough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M. and Wolf, C.R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus. Nature, 347, 773-776.
47. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T and Meyer, U. (1990) Multiple mutations of the human cytochrome p450IID6 gene (CYP2D6) in poor metabolizers of debrizoquine. J. Biol. Chem., 265, 17209-17214.
48. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M. and Meyer, U.A. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/ sparteine polymorphism. Am. J. Hum. Genet., 48, 943-950.
49. 1934-A base change in intron 3 of a mutant CYP2D6 allele results in an abberant 3′ splice recognition site. Am. J. Hum. Genet., 47, 994-1001.
50. Spurr, N, Cough, A.C., Smith, D. and Wolf, R. (1991) Genetic analysis of cytochrome P450 system. Methods Enzymol., 206, 149-166.
51. Breslow, N.E. and Day, N.E. (1980) Statistical Methods in Cancer Research. vol. I. IARC Scientific Publications, Lyon, France.
52. Shields, P.G. and Harris, C.C. (1991) Molecular epidemiology and the genetics of environmental cancer. J. Am. Med. Assoc., 266, 681-687.
53. Shields, P.G. (1993) Inherited factors and environmental exposures in cancer risk. J. Occup. Med., 35, 34-41.
54. Harris, C.C. (1989) Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis, 10, 1563-1566.
55. Board, P.G. (1981) Biochemical genetics of glutathione-S-transferase in man. Am. J. Hum. Genet., 33, 36-43.
56. Bell, D.A., Thompson, C.L., Taylor, J., Miller, C.R., Perera, F., Hsieh, L.L. and Lucier, G.W. (1992) Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ. Environ. Health Perespect., 98, 113-117.
57. Strange, R.C., Matharoo, B., Faulder, G.C., Jones, P., Cotton, W., Elder, J.B. and Deakin, M. (1991) The human glutathione-S-transferases: a case-control study of the incidence of the GSTM1 0 phenotype in patients with adenocarcinoma. Carcinogenesis, 12, 25-28.
58. Smith, M.T., Evans, C.G., Dane-Setzer, P., Castro, V., Tahir, M.K. and Mannervik, B. (1989) Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res., 49, 2621-2625.
59. Strange, R.C. (1993) The glutathione S-transferase GSTM1 locus and cancer susceptibility. In Tew, K.D., Picket, C.B., Mantle, T.J., Mannervik, B. and Hayes, J.D. (eds), Structure and Function of Glutathione Transferases. CRC Press Inc., Boca Raton, Florida, pp. 175-186.
60. Leaf, C.D., Wishnok, J.S. and Tannenbaum, S.R. (1989) Mechanisms of endogenous nitrosation. Cancer Surv., 8, 323-324.
61. Bartch, H., Oshima, H., Pagnatelli, B. and Calmels, S. (1992) Endogenously formed N-nitroso compounds and nitrosating agents in human cancer etiology. Pharmacogenetics, 2, 212-217.
62. Weitzman, S.A. and Gordon, L.I. (1990) Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood, 76, 655-663.
63. Weisburger, J.H. and Weisburger, E.K. (1972) Biochemical formation and pharmacological, lexicological, and pathological properties of hydroxylamines and hydroxamic acids. Pharmacol. Rev., 25, 1-66.
64. Lower, G.M. (1982) Concepts in causality: chemically induced human bladder cancer. Cancer, 49, 1056-1066.
65. Webbe, G. (1982) The life cycle of the parasite. In Jordan, P. and Webbe, G. (eds), Schistosomiasis: Epidemiology, Treatment and Control, Heinemann, London, pp. 21-46.
66. El-Mouelhi, M. and Mansour, M.M. (1990) Hepatic drug conjugation/ deconjugation in hepatosplenic schistosomiasis. Biochem. Pharmacol., 40, 1923-1925.
67. 6-Alkylguanine-DNA-alkyltransferase activity in relation to promutagenic methylation damage in bladder DNA from humans predisposed to bladder cancer associated with schistosomiasis. Eur. J. Cancer, 27, 46.
68. Badawi, A.F., Mostafa, M.H. and O'Connor, P. (1992) Involvement of alkylating agents in schistosome-associated bladder cancer: the possible basic mechanisms of induction. Cancer Lett., 63, 171-188.
69. Badawi, A.F., Cooper, D.P., Mostafa, M.H., Doenhoff, M.J., Probert, A., Padriac, F., Cooper, R. and O'Connor, P.J. (1993) Promutagenic methylation damage in liver DNA of mice infected with Schistosoma mansoni. Carcinogenesis, 14, 653-657.
70. Masimirembwa, C.M., Johansson, I., Hassler, J.A. and Ingelman-Sundberg, M (1993) Genetic polymorphism of cytochrome P4502D6 in Zimbabwean population. Pharmacogenetics, 3, 275-280.
71. Dahl, M.L., Johansson, I., Porsmyr-Palmertz, M., Ingelman-Sundberg, M. and Sjoqvist, F. (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther., 52, 12-17.
72. Wang, S.L., Huang, J., Lai, M.D., Liu, B.H. and Lai, M.L. (1993) Molecular basis for genetic variation in debrisoquine hydroylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin. Pharmacol. Ther., 53, 410-418.
73. Evans, W.E., Relling, M.V., Rahman, A., McLeod, H.L., Scott, E.P. and Lin, J-S. (1993) Genetic basis for low prevalence of deficient CYP2D6 oxidative drug metabolism in black Americans. J. Clin. Invest., 91, 2150-2154.
74. Hirvonen, A., Pelin, K., Tammilehto, L., Karjalainen, A., Mattson, K. and Linnainmaa, K. (1995). Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res., 55, 2981-2983.